Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amarin to file NDA a year earlier after positive MARINE trial

This article was originally published in Scrip

Executive Summary

Three years after Amarin Corp decided to explore the potential cardiovascular properties of its lead compound, AMR101, which it had been developing as Miraxion to treat Huntington's disease, the Irish company has unveiled positive, statistically significant top-line results from the 229-patient MARINE study, its first Phase III clinical trial in patients with very high triglyceride levels (500 mg/dL). This is a patient segment for which GSK's Lovaza is already approved. The study met the primary endpoint of percent change in triglyceride levels from baseline to week 12, for both 4g and 2g dose groups. While Amarin hopes to gain some purchase in the high triglycerides market, the compound is also in another Phase III study, ANCHOR, for treating people with much less elevated triglyceride levels, a much bigger patient group.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts